Thioguanine Tabloid and Varizig

• Generic Name: thioguanine
• Dosage Forms: n.a.
• Other Brand Names: Tabloid

Remission induction (in combination with other antineoplastic agents) in acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL).

Has been used with other antineoplastic agents in regimens of consolidation therapy for AML following induction of a complete remission; optimal regimen of such therapy in prolonging remissions remains to be established but is typically administered short-term.

Not recommended for maintenance or long-term continuous therapy. (See Hepatic Effects under Cautions.)

• Generic Name: varicella zoster immune globulin
• Dosage Forms: injection, solution
• Other Brand Names: Varizig

Varicella zoster (commonly known as chickenpox) is a common childhood disease that causes fever, skin rash, and a breakout of fluid-filled blisters on the skin. Chickenpox is usually mild, but it can be serious or even fatal in young infants, in adults, and in people who have a weak immune system. It can lead to severe skin infection, breathing problems, brain damage, or death.

When varicella zoster virus becomes active again in an adult, it can cause herpes zoster (also called shingles) which causes painful blisters, skin infections, severe nerve pain, and hearing or vision problems that can last for months or years.

Chickenpox is spread from person to person through the air, or by coming into contact with the fluid from a chickenpox blister.

Varizig is used in adults, children, and babies (including newborn or premature infants) who could become severely ill from exposure to varicella zoster virus. Varizig is also for use in pregnant women.

Varizig is used after exposure in people who have already come into contact with varicella virus. This medicine can help keep symptoms of the virus from becoming severe or life-threatening.

This medicine will not treat an active infection that has already developed in the body.

Varizig may also be used for purposes not listed in this medication guide.